دورية أكاديمية
أعرض في EDS

Effect of Non-ablative Medical Therapy on Progression of Hearing Loss in Menière's Disease: A Systematic Review and meta-Analysis.

التفاصيل البيبلوغرافية
العنوان: Effect of Non-ablative Medical Therapy on Progression of Hearing Loss in Menière's Disease: A Systematic Review and meta-Analysis.
المؤلفون: Thompson-Harvey A; Department of Otolaryngology-Head & Neck Surgery, University of Virginia, Charlottesville, Virginia., Pyle M; Department of Otolaryngology-Head & Neck Surgery, University of Miami Miller School of Medicine, Miami, Florida., Harvey E; Department of Otolaryngology & Communication Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin., Harris MS; Department of Otolaryngology & Communication Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin.
المصدر: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology [Otol Neurotol] 2024 Sep 01; Vol. 45 (8), pp. 833-839. Date of Electronic Publication: 2024 Jul 03.
نوع المنشور: Journal Article; Systematic Review; Meta-Analysis
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 100961504 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-4505 (Electronic) Linking ISSN: 15317129 NLM ISO Abbreviation: Otol Neurotol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, c2001-
مواضيع طبية MeSH: Meniere Disease*/therapy , Meniere Disease*/surgery , Hearing Loss*/etiology , Disease Progression*, Humans ; Audiometry, Pure-Tone
مستخلص: Objective: To systematically review how audiometric data change over time in patients with Menière's disease (MD) undergoing non-ablative medical therapy.
Databases Reviewed: Medline (via PubMed), Scopus, Web of Science, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Google Scholar.
Methods: A systematic review and meta-analysis of the literature was performed. Adult patients undergoing non-ablative medical therapy and reported duration of disease or follow-up were included and pooled estimates of pure-tone average (PTA) were tabulated. Studies were excluded if they did not use established MD, did not have pure-tone average (PTA) audiometric data, underwent ear surgery or ablative therapies, and were systematic reviews or case reports.
Results: Out of 198 articles meeting full eligibility, 13 studies, involving 950 patients with MD, were included in the review and further analyzed. No effect on progression of PTA from initial diagnosis was seen between the different medical therapies within 2 years of non-ablative medical treatment. There was a significant worsening of PTA after 2 year, regardless of treatment used. High levels of heterogeneity among studies were noted up to 6 months from diagnosis ( I2 = 79%), likely reflecting differences in patient characteristics, treatment regimens, and study design. Overall, the risk of bias was low for the majority of included studies.
Conclusions: Patients diagnosed with MD who are undergoing non-ablative medical therapy should be counseled on the likelihood of worsening of hearing loss over the course of the disease despite elected treatment.
Competing Interests: The authors disclose no conflicts of interest.
(Copyright © 2024, Otology & Neurotology, Inc.)
References: Friberg U, Stahle J, Svedberg A. The natural course of Meniere's disease. Acta Otolaryngol Suppl 1984;406:72–7.
Lee CS, Paparella MM, Margolis RH, Le C. Audiological profiles and Menière's disease. Ear Nose Throat J 1995;74:527–32.
Kotimäki J, Sorri M, Muhli A. Prognosis of hearing impairment in Ménière's disease. Acta Otolaryngol Suppl 2001;545:14–8.
Belinchon A, Perez-Garrigues H, Tenias JM. Evolution of symptoms in Ménière's disease. Audiol Neurootol 2012;17:126–32.
Filipo R, Barbara M. Natural history of Menière's disease: Staging the patients or their symptoms? Acta Otolaryngol Suppl 1997;526:10–3.
Tokumasu K, Fujino A, Naganuma H, Hoshino I, Arai M. Initial symptoms and retrospective evaluation of prognosis in Menière's disease. Acta Otolaryngol Suppl 1996;524:43–9.
Sajjadi H, Paparella MM. Meniere's disease. Lancet 2008;372:406–14.
Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology–Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:181–5.
Lopez-Escamez JA, Carey J, Chung W-H, et al. Diagnostic criteria for Meniere's disease. J Vestib Res 2015;25:1–7.
Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. Otolaryngol Head Neck Surg 2020;162:S1–S55.
Luxford E, Berliner KI, Lee J, Luxford WM. Dietary modification as adjunct treatment in Ménière's disease: Patient willingness and ability to comply. Otol Neurotol 2013;34:1438–43.
Thirlwall AS, Kundu S. Diuretics for Ménière's disease or syndrome. Cochrane Database Syst Rev 2006;2006:Cd003599.
Crowson MG, Patki A, Tucci DL. A systematic review of diuretics in the medical management of Meniere's disease. Otolaryngol Head Neck Surg 2016;154:824–34.
Murdin L, Hussain K, Schilder AGM. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev 2016;2016:CD010696.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol 2021;134:178–89.
Pyle M, Thompson-Harvey A, Harris MS. Long-term hearing outcomes in Meniere's disease patients undergoing medical management. PROSPERO 2021 CRD42021246483 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021246483 . Accessed June 25, 2024.
Pearson BW, Brackmann DE. Committee on hearing and equilibrium guidelines for reporting treatment results in Meniere's disease. Otolaryngol Head Neck Surg 1985;93:579–81.
Monsell EM. New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology–Head and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:176–8.
OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence . Oxford, England: Oxford Centre for Evidence-Based Medicine.
Pérez N, Espinosa JM, Fernández S, García-Tapia R. Use of distortion-product otoacoustic emissions for auditory evaluation in Menière's disease. Eur Arch Otorhinolaryngol 1997;254:329–42.
Teggi R, Gatti O, Sykopetrites V, et al. Association of cinnarizine and betahistine in prophylactic therapy for Meniere's disease with and without migraine. Acta Otorhinolaryngol Ital 2014;34:349–53.
Kinney SE, Sandridge SA, Newman CW. Long-term effects of Ménière's disease on hearing and quality of life. Am J Otol 1997;18:67–73.
Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: A two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005;133:285–94.
Suslu N, Yilmaz T, Gursel B. Utility of immunologic parameters in the evaluation of Meniere's disease. Acta Otolaryngol 2009;129:1160–5.
Aoki M, Wakaoka Y, Hayashi H, et al. The relevance of hypothalamus-pituitary-adrenocortical axis-related hormones to the cochlear symptoms in Ménière's disease. Int J Audiol 2011;50:897–904.
Monzani D, Barillari MR, Alicandri Ciufelli M, et al. Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: A 10-year experience. Acta Otorhinolaryngol Ital 2012;32:393–403.
Lavinsky J, Wolff ML, Trasel AR, Valerio MM, Lavinsky L. Effect of hyperinsulinism on sensorineural hearing impairment in Ménière's disease: A cohort study. Otol Neurotol 2014;35:155–61.
Sato G, Sekine K, Matsuda K, et al. Long-term prognosis of hearing loss in patients with unilateral Ménière's disease. Acta Otolaryngol 2014;134:1005–10.
Albu S, Chirtes F, Trombitas V, et al. Intratympanic dexamethasone versus high dosage of betahistine in the treatment of intractable unilateral Meniere disease. Am J Otolaryngol 2015;36:205–9.
Albu S, Nagy A, Doros C, et al. Treatment of Meniere's disease with intratympanic dexamethazone plus high dosage of betahistine. Am J Otolaryngol 2016;37:225–30.
Seyed Tootoonchi SJ, Ghiasi S, Shadara P, Samani SM, Fouladi DF. Hearing function after betahistine therapy in patients with Ménière's disease. Braz J Otorhinolaryngol 2016;82:500–6.
Fukushima M, Ueno Y, Kitayama I, et al. Assessment of the progression of vertical semicircular canal dysfunction and increased vestibular endolymphatic hydrops in patients with early-stage Ménière disease. JAMA Otolaryngol Head Neck Surg 2020;146:789–800.
Savastano M, Guerrieri V, Marioni G. Evolution of audiometric pattern in Meniere's disease: Long-term survey of 380 cases evaluated according to the 1995 guidelines of the American Academy of Otolaryngology–Head and Neck Surgery. J Otolaryngol 2006;35:26–9.
Zhang Y, Liu B, Wang R, Jia R, Gu X. Characteristics of the Cochlear symptoms and functions in Meniere's disease. Chin Med J (Engl) 2016;129:2445–50.
Huppert D, Strupp M, Brandt T. Long-term course of Menière's disease revisited. Acta Otolaryngol 2010;130:644–51.
Havia M, Kentala E, Pyykkö I. Hearing loss and tinnitus in Meniere's disease. Auris Nasus Larynx 2002;29:115–9.
Zhang W, Xie J, Li S, Zhang B. Correlation between quantitative value of endolymphatic hydrops and hearing threshold using magnetic resonance imaging. Ann Otol Rhinol Laryngol 2023;132:1149–55.
Webster KE, George B, Lee A, et al. Lifestyle and dietary interventions for Ménière's disease. Cochrane Database Syst Rev 2023;2:CD015244.
Hussain K, Murdin L, Schilder AG. Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome. Cochrane Database Syst Rev 2018;12:CD012173.
James AL, Burton MJ. Betahistine for Menière's disease or syndrome. Cochrane Database Syst Rev 2001;2001:CD001873.
Van Esch B, van der Zaag-Loonen H, Bruintjes T, van Benthem PP. Betahistine in Ménière's disease or syndrome: A systematic review. Audiol Neurootol 2022;27:1–33.
Webster KE, Lee A, Galbraith K, et al. Intratympanic corticosteroids for Ménière's disease. Cochrane Database Syst Rev 2023;2:CD015245.
Hoa M, Friedman RA, Fisher LM, Derebery MJ. Prognostic implications of and audiometric evidence for hearing fluctuation in Meniere's disease. Laryngoscope 2015;125(Suppl 12):S1–12.
تواريخ الأحداث: Date Created: 20240703 Date Completed: 20240814 Latest Revision: 20240815
رمز التحديث: 20240815
DOI: 10.1097/MAO.0000000000004251
PMID: 38956802
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-4505
DOI:10.1097/MAO.0000000000004251